Dear Colleagues,
A very warm welcome on behalf of the Scientific Program Planning Committee and PDA. We are pleased to invite you to join us for the 10th edition of the 2022 PDA Virus Conference to take place as a face-to-face event on 20-21 June 2022 in Brussels/Belgium.
This global meeting is organized in close collaboration with an excellent Scientific Program Planning Committee which includes European and U.S. FDA regulators, industry experts, supplier specialists, and dedicated PDA Europe support.
The overall program is designed to provide an update on regulatory expectations and the scientific framework around the virus safety of plasma-derived and biotechnology medicinal products, as well as the particularly innovative cell- and gene-therapies.
Similar to earlier events in this long-standing series, current and newly emerging viral threats, viral safety considerations around the selection of low risk starting materials, virus detection and identification methods and strategies, and the design and validation of virus inactivation and removal process will be key topics for discussion. In addition, intensified continuous manufacturing processes and their potential impact on facility design and viral safety will also be considered.
After a sequence of online-only events, forced by the emergence of SARS-CoV-2, the 2022 PDA Virus Conference will provide attendees the unique opportunity to re-gather for interactive discussions and benchmarking, as well as to reinvigorate social interactions. A discussion forum that allows for the direct interaction between industry and regulators will continue to support the wider industry and improve the current understanding and acceptance of new technologies, highlight new and emerging viral risks and explain novel regulatory approaches.
Panel discussions and ample networking opportunities will complement an impressive scientific program and make it a worthwhile and well-rounded experience for you.
We look forward to meeting you in person in Brussels!
Sincerely,
The Chairs
Alison Armstrong, Merck KGaA,
Thomas Kreil, Takeda
SCIENTIFIC PROGRAM PLANNING COMMITTEE
- Alison Armstrong, Merck KGaA, Chair
- Thomas R. Kreil, Takeda, Chair
- Andy Bailey, ViruSure
- Johannes Blümel, Paul-Ehrlich-Institut
- Qi Chen, Genentech/Roche
- Arifa S. Khan, U.S. FDA
- Sean O’Donnell, Eli Lilly & Company
- Sebastian Teitz, Asahi Kasei
- Josh Eaton, PDA
- Falk Klar, PDA
- Stefanie Nebelin, PDA, Manager Programs & Events